⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 7, 2026Australasian Journal of DermatologyOpen Access

Dupilumab's Real‐World Efficacy and Safety Across Age Groups for Children and Adolescents With Paediatric Atopic Dermatitis

Paul Sun Woo Kim Jacqueline Tu Kelvin Truong Gloria Fong William Luu Peter Barclay Melanie Wong Li‐Chuen Wong

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate the real-world effectiveness and safety of dupilumab in treating paediatric atopic dermatitis.
Observed paediatric patients receiving dupilumab treatment
Evaluated improvements in skin condition
Assessed safety outcomes by age group
Significant improvements in atopic dermatitis symptoms were noted
Safety profile of dupilumab was acceptable across different ages
Efficacy was consistent, regardless of patient age

Implication

Observational study reports dupilumab improves outcomes in children and adolescents, indicating strong effectiveness across ages.

Abstract

Paediatric dupilumab patients experienced significant improvements with an acceptable safety profile, independent of age.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kim et al. (2026) studied this question.

synapsesocial.com/papers/69d895206c1944d70ce061ad https://doi.org/10.1111/ajd.70118

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Dupilumab Efficacy and Safety Among Different Ages and Age of Onset of Atopic Dermatitis: Real‐World ExperienceRCT · 2026
2Dupilumab treatment in paediatric atopic dermatitis (2 to 18 years): Spanish multicentre retrospective real-life study2024 · 12 citations
3Dupilumab in pediatric atopic dermatitis: real-world evidence from two national centers2024 · 1 citations
4Real-Life Effectiveness, Safety, and Growth Outcomes of Dupilumab in Children Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis: A Multicenter Retrospective Study from an Italian NPP ProgramCohort Study · 2026 · 1 citations
5Efficacy and Safety of Dupilumab in Children Aged 6 months–11 years Old With Atopic Dermatitis: A Systematic Review and Meta‐AnalysisMeta-Analysis · 2026

More related papers

Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study2024
Long-Term Safety and Efficacy of Dupilumab Treatment in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis2026
The Safety Data of Dupilumab for the Treatment of Moderate‑to‑Severe Atopic Dermatitis in Infants, Children, Adolescents, and Adults2025

More from Australasian Journal of Dermatology

Real‐World Outcomes of Rituximab in Pemphigus: An Australian Tertiary CohortSat,
Location, Location, Location in Melanoma BiologyFri,